Thank highlights of you, XX% recently revenue thank Jacob, our of our We third third completed versus ago. call. to quarter a XXXX. some a and with you, posted joining I'd begin year gain like everyone, of quarter for
We patients. in make end-user units posterior develop we ILUVIEN Horus, the private an ILUVIEN. pursue in announced insurer rights agreement France. grow signed a We distributor and Europe Italy. indication Africa. -- secured in East, for a We our the our Middle partnership in with in utilizing ILUVIEN largest EU, doctors Irish we demand the and continue that first announced to with And more We available with to to Ireland to uveitis, the secondary sold
variation significant Earlier made the label Europe. the from plan we have on uveitis positive in this for cash told near progress toward you flow in following delivering posterior future. operations we year, We
so level. growing to expenses contain do revenues through while an at appropriate by We demand, expected our operating working increasing end-user to
quarter earlier, in increased to third an quarter XXXX discussed the in the demand U.S. third of the to driven as to third just by noted in was country, compared and increase third XXXX. of European demand compared quarter's continues I where sold period end-user quarter we grew the This of from XXXX. increase end-user increasing increase in ads same second Global conference to in by driven XX% X% was XXXX. demand revenues in of the of As the the which XXXX call. we last quarter the X% an approximately Germany, compared direct, of that quarter International stock recover by the in in primarily XX% as demand
increase posting growth, third to of compared the returned in end-user U.K. in a XXXX. quarter demand to significant demand Additionally,
variances these time. past, two is due our the extended revenue to timing discussed an purchases and we note by As end-user growth to in distributors. important between differences demand over the It's period out have large of balance and that
more period growth using ILUVIEN demand drug ILUVIEN only their of to to that XXXX. September For strategy. on part end-user with example, end-user GAAP efforts, global the in same physicians DME the dosing to and believe XX% continuous begun growth daily XXth, are treatment micro is realize, them the Physicians the our the have through is months treat revenue frequently nine is paradigm that during consistently indicates XX% a enables XXXX, growth to ended We change demand as compared in basis. that
anticipated, physicians the the office third Expenses was during As quarter. because period of of of the second seasonality this the this place major during ophthalmology bulk the July the conferences year, world during third during during quarter, incurred the typically the higher our and where in also revenue of cost the since in take in August out months. vacationing many half subject summer the are and Europe to U.S. are
path and that expenses the the income revenue XX% from from comparable positive the ended approximately nine period $X.X XXXX, in the the of decrease. operating our demonstrates and numbers, expenses operating we we XX% globally operating During of in And same in our XX% from our comparable decreased approximately months believe are the the for year, comparable in a about period during the delivering expenses into XXXX, September $X.X the for more we quarter of are operations operating XXXX for third by period quarter Rick from an running that remained growth million on than period go reduced will in approximate consistently third prior XXXX, the expenses but our less the year. have million XXth, XXXX, near-term. by detail
reinvesting are I anticipate salesforce our cost XX% revenue spend. which As and we data. drive our in acceptance topline our revenue and in the the Prospectively, marketing said remain our get in previously, we included XXXX, Europe consideration our confident growth our the efforts, to further measures with future. in our salesforce pleased we customers from and we of marketing in I based upon regarding will U.S. which at will control reducing that continue believe ILUVIEN's in real-world the grow feedback growth
efficacy, have consistently and reflecting something ophthalmology, real-world day. patients, with that every pivotal drug unique trials the enables We treat to frequency for disease our the treatment physicians only reduced in
therapy offer the not had studies. I we mirror our you to only and ILUVIEN. research insight competitors as Society like it their they to unlike team fully this I'd are real-world now to along compelling time, do presented with our provide meeting. was ILUVIEN a chronic presented with in I'd been the data. why the Our is this call story and Meeting. tell a it cannot two of medical usage in at American last ILUVIEN, believe with comparable Retina have this In our disease European Society share a scratching sales in into But acute more small on surface for just had data that you the this team final with discussed some of salesforce The U.S. to data. very we like provide now. presenting quarter, Specialists all our And the this and data meetings; of Retina major I past
As study today. patient as encompasses treat These for the a alternatives using study represent the four treatments to prior injection. their that introducing over groups eyes The receive practices the the effectiveness to before DME physicians well ILUVIEN DME. patients patients treated as four This of getting reminder, at their ILUVIEN. ILUVIEN ILUVIEN ability user illustrates XXX in were patients reduce number lines the to with injection and its with vision of XX representing user chart XXX
or and for the anti-VEGF worse these lines, green prior the visions two that other top I ILUVIEN. effectively with shows of patients was other line sake, data data Arguably, XX/XX were bottom-line on Arguably, patients drive. They patients patients therapy. can prior truly -- brevity anti-VEGF topline they to to therapy. injection treated legally and those the for were unresponsive than The For with want the whose injection to shows of XX/XXX The at good and being the shows ILUVIEN. vision two are to bottom. focus of
even the Looking ILUVIEN side months patients before average, and their right the you left look was on their of chart three the But decline. see after ILUVIEN, can chart for injection. treated, at DME vision marked stable every were or of the at the side that
vision, months maintained with from ILUVIEN on once to an these For the every gave every the those but average patients XX patients topline their vision, went three from good once months. treatment. treatment they independence good
they vision experienced XX letters or improved the vision four For ILUVIEN group, a average treatment. reduction an their of an gained and patients while improved lines, on These burden. in treatment those by bottom having the
ILUVIEN. recurrence of of patients. patients the additional with evidence to and it provides reduce types We the the illustrates patients ability broadly. of ILUVIEN fewer the with Importantly, the highlights clinical of and Users our the the intraocular to XX% efficacy of The opportunity study This well sales and demonstrates ILUVIEN's From it's eyes dosing pressure, intraocular edema. data of and other study in reduction medical of expanded the as selling this the value in of and number ILUVIEN treatment the [ph] data. DME data to frequency believe it patients the one all of trials, known rise, in patients. risk treat that are European micro is that of treatments steroids greatest XX% the no IOP supports continuous treatment required throughout increase also for why is finding daily roughly ILUVIEN team addressed DME. consistent excited in or This all share challenges this
illustrate study protocols. is trial easily in within physicians in difference in effect steroids objection of study was managed treatment all an the can to course provides user because corticosteroids, in nevertheless and patients performance the ILUVIEN. a The to of setting. couple treated the rather prior of to of side it a as with IOP key drops, a user This using profile this is is requires of clinic patients retinal raised a U.S. key the conducted to were the clinical us concern trial of important be to ILUVIEN DME. which IOP-lowering While the with The label a clinical than insights majority
corticosteroid no patient's demonstrates treatment. can As of IOP treatment this there in following ILUVIEN upon administration. based the table chart, you with responses second ILUVIEN increase in after was significant see prior with predictability This mean IOP
statistically see difference after to and significant that was there ILUVIEN. IOP before can with You no respect
large data team that prior XX study had the this patients IOP mercury. same on this Rather, in label symposium new XXX were over physicians in over we posterior the by use a shown we in prior provides which guide quarter, the Recall, including the of we having results with preparing demand. the the corticosteroid where managing appear user to of within the data driving evidenced the confidence well to from with been with scientific IOP. ILUVIEN Germany. announced the follow-up In corticosteroid millimeters in to utilized the is doctors from the experienced the EURETINA year, believe accordance the the sources. the helping a announcement, clinic trials. injection of above IOP our progressing three-year provide the uveitis, attendees variety non-infection presented, out of This all patients as Confirming program, third The Europe, at the eye. license Europe user XXX with greater year, the pSivida, study real-world conference Importantly, segment an Since with Further, with patients in to well. test now a of physicians XX solely to with we data the have past did in ILUVIEN data label end-user our not has European using this posterior prior have Barcelona, rise IOP performance consistent a over past been [Indiscernible] with eyes for of and any screen was manage from response. of is affecting as following IOP In and mitigate the study ILUVIEN. our inflammatory to This early label increasing the our of for expanded in extension of value emerged Europe. disease have that quarter corticosteroid potentially validates is ILUVIEN,
coming with uveitis XX-month planned is data, key is in a have from uveitis. Phase of enrolled believe recurrence indication. patients to anticipated justifies MHRA points study, XXX trials. We endpoint collection. parallel multicenter two reduction couple I'd a data XXX, The you were the segment, the a six-month this like which non-infectious posterior and XXX of a submission. of approval in affecting comprised compiled for III which we primary data NIU-PS, The the share the stands studies, read-out the with primary the and on
chart, recurred with of Sham fluocinolone treated on you significant. the this approximately with This fluocinolone treated uveitis the As acetonide XX.X% in injected, was statistically with only patients while see can patients in acetonide. XX% XX.X% Injection, of difference highly of
from sham, are data ocular with are with is rises disease, We're physicians ILUVIEN are data of rates study for discussions main two six are with months at at expectations. safety, all too specialized XXX in thread but Europe at side of XX From study live line from and you that the for injection, the typically data patients intraocular And Uveitis aware, our and higher of the pressure Looking encompasses in in effects. working age different a looking than the treatment blindness. this and likely often potential development need the XXX. months' clear. corticosteroid as the cataract parameters clinical
the standard-of-care will believe steroid so are high. patients. motivation systemic step to is in associated treatment these micro a logical the an problems this very the low-dose uveitis, and are of managing While continuous We provide physicians disease. progressive that dosing lower is alternative already DME, side of the to effects intravitreal, than posterior Steroids, non-infection accustomed unique treat with both in
discuss submission. We the MHRA have with a fourth meeting to in the quarter
to keeping With in you more for regarding off go I financials. filing marketing detail look commence hand file we like for Our proved label approval plan is XXXX of Rick? posterior successful, posterior apprised which to quarter DME. ILUVIEN for XX in would a variation progress to countries to on to XXXX. the and our in our forward then XXXX in Rick by to uveitis to first would If are the We that, Europe our of we in expect to treat of it our product the uveitis.
